medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Número 4

<< Anterior Siguiente >>

Ann Hepatol 2016; 15 (4)


Thymosin β10 as a predictive biomarker of response to 5-fluorouracil chemotherapy in cholangiocarcinoma

Sribenja S, Natthasirikul N, Vaeteewoottacharn K, Sawanyawisuth K, Wongkham C, Jearanaikoon P, Wongkham S

Idioma: Ingles.
Referencias bibliográficas: 47
Paginas: 577-585
Archivo PDF: 299.80 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Khan MA, Masood N, Husain N, Ahmad B, Aziz T, Naeem A. A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center. J Pak Med Assoc 2012; 62:430-4.

  2. Ramia JM. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointestinal Oncol 2013; 5: 171-6.

  3. Andre T, Tournigand C, Rosmorduc O, Provent S, Maindrault- Goebel F, Avenin D, Selle F, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-43.

  4. Cho JY, Paik YH, Chang YS, Lee SJ, Lee DK, Song SY, Chung SB, et al. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/ metastatic biliary tract carcinoma. Cancer 2005; 104: 2753-8.

  5. Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98: 309-15.

  6. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, Rosenberg WM, et al.; British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 2012; 61:1657-69.

  7. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, Pawlik TM, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol 2014; 60: 1268-9.

  8. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-81.

  9. National Comprehensive Cancer Network (NCCN) guidelines. V2.2012. Available from: www.nccn.org

  10. Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, Verslype C, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int 2008; 28: 1370-80.

  11. Henderson MJ, Haber M, Porro A, Munoz MA, Iraci N, Xue C, Murray J, et al. ABCC multidrug transporters in childhood neuroblastoma: clinical and biological effects independent of cytotoxic drug efflux. J Natl Cancer Inst 2011; 103: 1236-51.

  12. Sampath D, Rao VA, Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene 2003; 22:9063-74.

  13. Pinedo HM, Peters GF. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988; 6: 1653-64.

  14. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003; 3: 330-8.

  15. Maxwell PJ, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, et al. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.Cancer Research 2003; 63: 4602-6.

  16. Boyer J, Maxwell PJ, Longley DB, Johnston PG. 5-Fluorouracil: identification of novel downstream mediators of tumour response. Anticancer Research 2004; 24: 417-23.

  17. Namwat N, Amimanan P, Loilome W, Jearanaikoon P, Sripa B, Bhudhisawasdi V, Tassaneeyaku W. Characterization of 5- fluorouracil-resistant cholangiocarcinoma cell lines. Chemotherapy 2008; 54: 343-51.

  18. Wattanawongdon W, Hahnvajanawong C, Namwat N, Kanchanawat S, Boonmars T, Jearanaikoon P, Leelayuwat C, et al. Int J Oncol 2015; 47: 398-410.

  19. Sribenja S, Sawanyawisuth K, Kraiklang R, Wongkham C, Vaeteewoottacharn K, Obchoei S, Yao Q, et al. Suppression of thymosin beta10 increases cell migration and metastasis of cholangiocarcinoma. BMC Cancer 2013; 13: 430-14.

  20. Srimunta U, Sawanyawisuth K, Kraiklang R, Pairojkul C, Puapairoj A, Titipungul T, Hahnvajanwong C, et al. High expression of ABCC1 indicates poor prognosis in intrahepatic cholangiocarcinoma. Asian Pac J Cancer Prev 2012; 13 (Suppl.): 125-30.

  21. Thongprasert S. The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005; 16 (Suppl. 2): ii93-ii6.

  22. Ramirez-Merino N, Aix SP, Cortes-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastro Oncol 2013; 5: 171-6.

  23. Butthongkomvong K, Sirachainan E, Jhankumpha S, Kumdang S, Sukhontharot OU. Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand. Asian Pac J Cancer Prev 2013; 14: 3565-8.

  24. Thunyaharn N, Promthet S, Wiangnon S, Suwanrungruang K, Kamsa-ard S. Survival of cholangiocarcinoma patients in northeastern Thailand after supportive treatment. Asian Pac J Cancer Prev 2013; 14: 7029-32.

  25. Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma.Gastroenterology 2013; 145: 1215-29.

  26. Tepsiri N, Chaturat L, Sripa B, Namwat W, Wongkham S, Bhudhisawasdi V, Tassaneeyaku W. Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines. World J Gastroenterol 2005; 11: 2748-53.

  27. Thanasai J, Limpaiboon T, Jearanaikoon P, Sripa B, Pairojkul C, Tantimavanich S, Miwa M. Effects of thymidine phosphorylase on tumor aggressiveness and 5-fluorouracil sensitivity in cholangiocarcinoma. World J Gastroenterol 2010; 16: 1631-8.

  28. Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, et al. Orotatephosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012; 18: 3955-61.

  29. Munoz-Garrido P, Garcia-Fernandez de Barrena M, Hijona E, Carracedo M, Marin JJ, Bujanda L, Banales JM. MicroRNAs in biliary diseases. World J Gastroenterol 2012; 18: 6189-96.

  30. O’Hara SP, Gradilone SA, Masyuk TV, Tabibian JH, LaRusso NF. MicroRNAs in Cholangiopathies. Curr Pathobiol Rep 2014; 2: 133-42.

  31. Pisarello MJ, Loarca L, Ivanics T, Morton L, LaRusso N. MicroRNAs in the cholangiopathies: Pathogenesis, diagnosis, and treatment. J Clin Med 2015; 4: 1688-712.

  32. Okamoto K, Miyoshi K, Murwaki Y. miR-29b, miR205 and miR- 221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells. PLoS ONE 2013; 8: e77623.

  33. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, et al. Involvement of humen micro-RNA in growth and response to chemotherapy in humancholangiocarcinoma cell lines. Gastroenterology 2006; 130: 2113- 129.

  34. To KK. MicroRNA: a prognostic biomarker and a possible druggable target for circumventing multidrug resistance in cancer chemotherapy. J Biomed Sci 2013; 20: 99.

  35. Haenisch S, Werk AN, Cascorbi I. MicroRNAs and their relevance to ABC transporters. Br J ClinPharmacol 2014;77:587-96.

  36. Tian W, Chen J, He H, Deng Y. MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications. Clin Transl Oncol 2013; 15: 335-42.

  37. Pan YZ, Zhou A, Hu Z, Yu AM. Small Nucleolar RNA-Derived MicroRNA hsa-miR-1291 Modulates Cellular Drug Disposition through Direct Targeting of ABC Transporter ABCC1. Drug Metabol Dispos 2013; 41: 1744-51.

  38. Li WQ, Li YM, Tao BB, Lu YC, Hu GH, Liu HM, He J, et al. Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 2010; 16: HY27-HY30.

  39. Mostert B, Sieuwerts AM, Bolt-de Vries J, Kraan J, Lalmahomed Z, van Galen A, van der Spoel P, et al. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Mol Oncol 2015; 9: 920-32.

  40. Mostert B, Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, van Galen A, Peeters DJ, et al. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Ann Oncol 2015; 26: 510-6.

  41. Onstenk W, Sieuwerts AM, Weekhout M, Mostert B, Reijm EA, van Deurzen CH, Bolt-de Vries JB, et al. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Lett 2015; 362: 36-44.

  42. Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q. Roles of thymosins in cancers and other organ systems. World J Surg 2005; 29: 264-70.

  43. Sribenja S, Li M, Wongkham S, Wongkham C, Yao Q, Chen C. Advances in thymosin beta10 research: differential expression, molecular mechanisms, and clinical implications in cancer and other conditions. Cancer Invest 2009; 27: 1016-22.

  44. Sribenja S, Wongkham S, Wongkham C, Yao Q, Chen C. Roles and mechanisms of beta-thymosins in cell migration and cancer metastasis: an update. Cancer Invest 2012; 31: 103-10.

  45. Li Z, Qu L, Zhong H, Xu K, Qiu X. Mechanism of thymosin beta 10 inhibiting the apoptosis and prompting proliferation in A549 cells. Chin J Lung Cancer (Zhongguofeiaizazhi) 2014; 17: 783-8.

  46. Wang H, Jiang S, Zhang Y, Pan K, Xia J, Chen M. High expression of thymosin beta 10 predicts poor prognosis for hepatocellular carcinoma after hepatectomy. World J Surg Oncol 2014; 12: 226.

  47. Zhang XJ, Su YR, Liu D, Xu DB, Zeng MS, Chen WK. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma. J Surgical Res 2014; 192: 487-93.




2020     |     www.medigraphic.com